At Miraca we believe in healthy collaboration for healthier patients, and this tenet applies also to our technology partnerships. To serve our physician clients, Miraca Life Sciences has carefully selected and partnered with a number of specialized vendors.

We work closely with each partner to offer solutions that maximize the efficiency of your practice.

  • gMed — We offer gMedConnect to gastroenterology practices for a low monthly subscription fee.
  • ProVation — Through Miraca's partnership with ProVation, you can add the ProVation MD endoscopy report writing software to your practice at an affordable price.
  • Modernizing Medicine — For dermatologists who use the EMA EMR, we have significantly enhanced how our pathologists use diagnostic information.

The Miraca team proudly brings these outstanding technology companies to our physician clients to enhance the day-to-day business of running your practice.

Miraca Life Sciences is investing in where the market is going: converged, cloud-ready, fully-integrated technology solutions. We expand the diversity of our offerings and our ability to deliver relevant practice solutions through our strategic relationships with leading specialty-specific vendors. Find the program that fits your business.

Continuous electronic connection with patients and healthcare partners is the business model of the new millennium. Downtime is not an option. That's why Miraca Life Sciences is offering practice solutions designed specifically for this new electronic economy. Miraca is aggressively building unique specialty-specific expertise with every technology partnership and e-business solution that we offer in order to provide customized architectures and products that fit your practice.

Importantly, our consulting expertise and implementation experience deepens and broadens our solution portfolio and industry capabilities. Miraca’s broad spectrum of best-in-class service offerings aims to meet your every business need, whether simple or complex.

Contact Miraca Life Sciences to learn how Miraca can assist your practice
Call 1.866.588.3280 or email

Choose Miraca for Your Patients

Learn more about Miraca's Anatomic Pathology services

Learn More »

The entire team is extremely helpful, very available and hands on! The pathologists always give accurate and specific information, they request stains and notify us every step of the way.
— Saaima Farooq, Administrator, and Andleeb Usmani, DO,
TruDerm PA, Wellington, Fla.

Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News

November 20, 2017

Avista Capital Partners Completes Acquisition of Miraca Life Sciences

IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Miraca Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc.

Continue reading the press release at the Avista website.

Continue reading

October 16, 2017

Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

IRVING, Texas, October 16, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early November. Since launching the InformTx service in June 2016, Miraca Life Sciences […]

Continue reading

October 3, 2017

Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future

SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered […]

Continue reading

September 22, 2017

Avista Capital Partners to Acquire Miraca Life Sciences

IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Continue reading press release

Continue reading

April 18, 2017

Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

Pathologists at Miraca Life Sciences contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Miraca Life Sciences participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Miraca, participation in the Philips study was a project of Miraca […]

Continue reading